Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1
45
about 18 years
18+
1 site in TX
What this study is about
Researchers are testing a new treatment called CAdVEC, which is an oncolytic adenovirus. The trial is also testing the safety and effectiveness of combining this treatment with HER2-specific autologous CAR T cells in people with advanced HER2-positive solid tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CAdVEC
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of patients with dose limiting toxicity (DLT) by CTCAE 5.0
Secondary: Disease Control Rate (DCR), Number of treatment related adverse events with grade 3 or greater severity by CTCAE 5.0, Overall Response Rate (ORR) according to RECIST1.1 criteria, Overall Survival (OS), Progression Free Survival (PFS)
Oncology